ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases

Ads

You May Also Like

Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers

                                                                  NANOBIOTIX PARTNERS WITH WEILL CORNELL MEDICINE ON PRE-CLINICAL STUDIES TO EVALUATE THE IMPACT ...

Shire plc : Notice of Results

Shire to announce second quarter 2018 results Dublin, Ireland - July 23, 2018 - ...

100,000 Orion Corporation A shares converted into B shares

  ORION CORPORATION      STOCK EXCHANGE RELEASE 5 OCTOBER 2016 at 9.00 a.m. EEST               ...